Alnylam Pharmaceuticals
ALNY
305 hedge funds and large institutions have $7.94B invested in Alnylam Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 115 increasing their positions, 94 reducing their positions, and 38 closing their positions.
32% more call options, than puts
Call options by funds: $139M | Put options by funds: $105M
22% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 94
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
1% less ownership
Funds ownership: 91.08% → 90.08% (-1%)
2% less funds holding
Funds holding: 310 → 305 (-5)
11% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 38
12% less capital invested
Capital invested by funds: $9.02B → $7.94B (-$1.08B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$125M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
+$83.6M |
| 3 |
JP Morgan Chase
New York
|
+$35.5M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$31.7M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$27.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$125M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$102M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$69M |
| 4 |
PA
Perceptive Advisors
New York
|
-$65.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$47.4M |
ALNY Hedge Fund Activity: Q3 2018 in Review
305 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2018, worth a combined $7.94B — down 12% from $9.02B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of ALNY and 34 opened new positions — a net loss of 4 holders — while 94 trimmed existing stakes and 115 added.
The largest buyer was Wellington Management Group, adding an estimated $125M. The largest seller was OrbiMed, exiting entirely with an estimated $125M sold.
- 305 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2018, down from 310 in Q2 2018.
- Funds reported $7.94B of Alnylam Pharmaceuticals stock for Q3 2018, down 12% quarter-over-quarter.
- 34 funds opened new Alnylam Pharmaceuticals positions in Q3 2018 and 38 closed out, a net change of -4 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2018 was Wellington Management Group, an estimated $125M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2018 was OrbiMed, an estimated $125M sold.
Based on aggregated 13F filings for Q3 2018.